《生命科学》 2023, 35(4): 437-447

纳米药物递送系统在基于化疗的联合治疗中的研究进展

朱　斌 , 陈思禹^* , 宋明明^*

中国药科大学生命科学与技术学院，南京 211198

摘　要：

肿瘤是一种病理过程复杂的疾病。大多数肿瘤患者接受化疗和放疗，但这些治疗通常只对部分有效，并产生各种严重的副作用。因此，有必要开发新的治疗策略。联合治疗是目前肿瘤治疗的热点，联合用药引起的多种协同作用是提高抗肿瘤活性的关键。纳米药物递送系统的出现对临床治疗产生了深远的影响。药物的体内递送常不能达到令人满意的治疗效果，而纳米药物递送系统可以实现肿瘤靶向给药，在提高抗肿瘤效果的同时降低药物的毒副作用。本文介绍了多种基于化疗的联合治疗方法，重点阐述了纳米药物递送系统在基于化疗的联合治疗中的运用，并对该领域面临的挑战和未来发展方向进行了展望。

通讯作者：陈思禹 , Email:siyuchen@cpu.edu.cn 宋明明 , Email:1520210049@cpu.edu.cn

Advances of nanocarrier-based drug delivery system in chemotherapy-based combination therapy

ZHU Bin , CHEN Si-Yu^* , SONG Ming-Ming^*

School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China

Abstract:

Tumor is a disease with complex pathological process. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. Combination therapy is a current hot topic in tumor therapy. Multiple synergistic effects elicited by combined drugs are essential in improving antitumor activity. The emergence of nanocarrier-based drug delivery systems (NDDSs) has a profound impact on general clinical treatment. In vivo delivery of drugs sometimes fails to achieve satisfactory therapeutic effects. NDDSs can realize tumor-targeted drug delivery, improve the anti-tumor effect and reduce the toxicity and side effects of drugs. This review introduces a variety of chemotherapy-based combination therapies, focuses on the application of NDDSs in chemotherapy-based combination therapies, and looks forward to the challenges and future development directions in this field.

Communication Author：CHEN Si-Yu , Email:siyuchen@cpu.edu.cn SONG Ming-Ming , Email:1520210049@cpu.edu.cn